Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment.

Allison W KurianPaul AbrahamseAnn S HamiltonJennifer L Caswell-JinScarlett Lin GomezTimothy J HoferKevin C WardSteven J Katz

Published in: JNCI cancer spectrum (2022)

BRCA1/2 PV carriers with HR-positive, HER2-negative breast cancer had twofold higher odds than noncarriers of receiving a platinum, as part of a more intensive chemotherapy regimen. This likely represents overtreatment and emphasizes the need to monitor how genetic testing results are managed in oncology practice.

Keyphrases

early stage
breast cancer risk
locally advanced
healthcare
primary care
palliative care
copy number
radiation therapy
quality improvement
neoadjuvant chemotherapy
chemotherapy induced
dna methylation
genome wide